Declining immune responsiveness with age may be driven by changes in immune cells — not by inflammation, as previously ...

"It is well recognized that human papillomavirus (HPV), hepatitis B virus, and other viruses can cause cancer; however, the ...

A comprehensive eight-year study examining audiological outcomes of newborns screened for congenital cytomegalovirus (cCMV) ...

Moderna announced its decision to cease development of its vaccine mRNA-1647, which was being designed to treat birth defects such as cytomegalovirus (CMV), following its failure to reach the primary ...

Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company’s investigational cytomegalovirus (CMV) vaccine. CMV is a ...

Oct 22 (Reuters) - Moderna (MRNA.O), opens new tab said on Wednesday it would stop developing its experimental vaccine to prevent cytomegalovirus, a virus that can cause birth defects, after it failed ...

Moderna had hoped its shot would be at least 49% effective at preventing CMV infections, substantially reducing the risk of passing the virus to newborns. But top-line data the company released ...

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women from the virus in a large phase 3 trial, the biotech announced in a ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Moderna said Wednesday afternoon that its ...

CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company's ...